Abstract:Protein aggregation is associated with various diseases, including Alzheimer and Parkinson as well as sickle cell disease (SCD). From a molecular point of view, protein aggregation depends on a complex balance of electrostatic and hydrophobic interactions mediated by water. An impressive manifestation of the importance of this balance concerns the human hemoglobin (HbA) mutant, HbS (sickle cell Hb), where a single substitution at the 6th position of HbA β-chains, from glutamic acid to valine, causes the polymerization of deoxygenated HbS (deoxy-HbS), responsible for SCD. HbS polymerization is believed to occur via a double nucleation mechanism initiated by the formation of HbS fibers (homogeneous nucleation), followed by fiber growth. Furthermore, it was proposed that homogeneous nucleation proceeds through a two-step mechanism, where metastable dense clusters play the role of nucleation precursors. Thus, hindering or delaying the formation of such precursors could represent a potential SCD therapeutic route. Here, we study, through molecular dynamics, the binding free energy and protein-protein contacts involved in the deoxy-HbS dimer aggregation and stabilization process. A binding free energy of ∼-14.0 ± 1 kcal/mol is estimated from a one-dimensional potential of mean force. Analysis of protein-protein interactions shows that both electrostatic and van der Waals interactions play an important role on the aggregation of HbS. With respect to the former, our results indicate that aggregation is largely favored by the formation of salt bridges (SB), mostly, Lys-Glu, Lys-Asp, and Heme-Lys SB, which outweigh electrostatic repulsions involving similar residues. Thus, our results suggest that a potential antisickling drug could be one with the ability to weaken or hinder the formation of a few SB between carboxylate and ammonium groups.

Cyclic Peptides as Aggregation Inhibitors for Sickle Cell Disease

Sickle Cell Hemoglobin Drugged with Cyclic Peptides is Aggregation Incompetent

Sickle Cell Hemoglobin "Drugged" with Cyclic Peptides Is Aggregation Incompetent

On the Binding Free Energy and Molecular Origin of Sickle Cell Hemoglobin Aggregation

Regioselective covalent modification of hemoglobin in search of antisickling agents

Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease

Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions

Simultaneous polymerization and adhesion under hypoxia in sickle cell disease.

Evaluating sheep hemoglobins with MD simulations as an animal model for sickle cell disease

Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.

Science Journals — AAAS

PGC-1α agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease

Probing the Twisted Structure of Sickle Hemoglobin Fibers via Particle Simulations.

Discovery of potent DNMT1 inhibitors against sickle cell disease using structural-based virtual screening, MM-GBSA and molecular dynamics simulation-based approaches

Haemoglobin F modulation in childhood sickle cell disease

Sickle cell disease as a vascular disorder

Red blood cell aggregation, aggregate strength and oxygen transport potential of blood are abnormal in both homozygous sickle cell anemia and sickle-hemoglobin C disease

Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia

Methemoglobin aggregation is modulated by the anti-sickling drug voxelotor

Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities